Altimmune Inc
Performance History
| Key Stats | |
|---|---|
| Open | $3.11 |
| Prev. Close | $3.11 |
| EPS | -1.54 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 10, 2023 |
| Dividend Yield % | 4.08% |
| Market Cap | $168.17M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 3.10 | 3.39 |
| 52 Week Range | 2.09 | 17.17 |
| Ratios | |
|---|---|
| P/B Ratio | 1.11 |
| Revenue | - |
| Operating M. % | -6,226.52% |
| Earnings | -$57.83M |
| Earnings Growth % | 18,000.00% |
| EBITDA Margin % | - |
| ROE % | -44.15% |
| EPS | -1.54 |
Score Breakdown
Score ( / 100) undefined
| ALT | Market |
|---|
Score ( / 100) undefined
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Altimmune Inc (ALT)
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Vipin K. Garg Ph.D.
- Headquarters
- Gaithersburg
- Employees
- 52
Keep an eye on Altimmune Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.